Figure 1.

Conceptual framework of the GBM-microbiome study design

(A) The GSC-005 GBM cohort compromises four experimental groups: naive (n = 5), control (n = 3), indoximod treated (n = 5), and Delta-24-RGDOX treated (n = 4). (B) The GL261-5 GBM cohort with a total of three experimental groups: control (n = 5), Delta-24-RGDOX and indoximod treated plus the IgG control antibody (n = 5), and Delta-24-RGDOX and indoximod treated plus the CD4 neutralizing antibody (n = 5). Study design outcomes include microbiota changes related to viroimmunotherapy treatment for both cohorts and association with mouse survival period for the GSC-005 GBM cohort. Created with BioRender.